Silk Road Medical, Inc. (SILK): Price and Financial Metrics

Silk Road Medical, Inc. (SILK): $57.15

-1.78 (-3.02%)

POWR Rating

Component Grades














  • SILK scores best on the Growth dimension, with a Growth rank ahead of 77.37% of US stocks.
  • SILK's strongest trending metric is Value; it's been moving up over the last 48 weeks.
  • SILK ranks lowest in Sentiment; there it ranks in the 18th percentile.

SILK Stock Summary

  • Silk Road Medical Inc's stock had its IPO on April 4, 2019, making it an older stock than merely 5.84% of US equities in our set.
  • SILK's price/sales ratio is 22.65; that's higher than the P/S ratio of 91.17% of US stocks.
  • As for revenue growth, note that SILK's revenue has grown 28.73% over the past 12 months; that beats the revenue growth of 76.43% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Silk Road Medical Inc are PRLB, NSPR, FLDM, APDN, and VYNE.
  • SILK's SEC filings can be seen here. And to visit Silk Road Medical Inc's official web site, go to

SILK Valuation Summary

  • SILK's price/sales ratio is 22.8; this is 100.88% higher than that of the median Healthcare stock.
  • SILK's EV/EBIT ratio has moved down 10.8 over the prior 29 months.
  • Over the past 29 months, SILK's EV/EBIT ratio has gone down 10.8.

Below are key valuation metrics over time for SILK.

Stock Date P/S P/B P/E EV/EBIT
SILK 2021-08-31 22.8 21.3 -42.3 -44.2
SILK 2021-08-30 21.9 20.4 -40.7 -42.4
SILK 2021-08-27 21.2 19.7 -39.3 -40.9
SILK 2021-08-26 20.8 19.4 -38.5 -40.1
SILK 2021-08-25 20.6 19.2 -38.2 -39.8
SILK 2021-08-24 20.6 19.2 -38.2 -39.8

SILK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SILK has a Quality Grade of C, ranking ahead of 29.09% of graded US stocks.
  • SILK's asset turnover comes in at 0.512 -- ranking 90th of 183 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows SILK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.512 0.745 -0.364
2021-03-31 0.435 0.725 -0.326
2020-12-31 0.444 0.717 -0.303
2020-09-30 0.458 0.714 -0.246
2020-06-30 0.472 0.721 -0.276
2020-03-31 0.510 0.743 -0.358

SILK Price Target

For more insight on analysts targets of SILK, see our SILK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.50 Average Broker Recommendation 1.5 (Moderate Buy)

SILK Stock Price Chart Interactive Chart >

Price chart for SILK

SILK Price/Volume Stats

Current price $57.15 52-week high $75.80
Prev. close $58.93 52-week low $43.11
Day low $55.18 Volume 250,400
Day high $59.53 Avg. volume 342,500
50-day MA $53.05 Dividend yield N/A
200-day MA $53.51 Market Cap 1.98B

Silk Road Medical, Inc. (SILK) Company Bio

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. The firm's devices enable vascular access via a puncture adjacent to the collarbone instead of the traditional approach of accessing the vascular system through the groin. Its products include ENROUTE Transcarotid Neuroprotection & Stent System. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

SILK Latest News Stream

Event/Time News Detail
Loading, please wait...

SILK Latest Social Stream

Loading social stream, please wait...

View Full SILK Social Stream

Latest SILK News From Around the Web

Below are the latest news stories about Silk Road Medical Inc that investors may wish to consider to help them evaluate SILK as an investment opportunity.

President And CEO Of Silk Road Medical Trades $648.17 Thousand In Company Stock

Erica Rogers, President And CEO at Silk Road Medical (NASDAQ:SILK), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 13, Erica Rogers bought 11,000 Silk Road Medical shares at a price of $1.60 per share, for a total of $17,600. They then sold their shares on the same day in the open market at a price of $57.32 to raise a total of $630,565 from the s

Yahoo | September 15, 2021

Silk Road Medical to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.

Intrado Digital Media | September 1, 2021

Embolic Protection Devices Market Will Showing Exceptional Growth in near Future, Key Players - Contego Medical, W. L. Gore & Associates, Silk Road Medical, Claret Medical, Allium Medical Solutions

The Embolic Protection Devices Market is expected to grow at a CAGR of 6.1 % and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020 The Embolic Protection Devices Market business research report by Decisive

OpenPR | August 24, 2021

First Ever Analysis of TCAR in Standard Surgical Risk Patients Demonstrates Clinical Benefits in Large Comparative Dataset

Large-Scale Analysis of TCAR in The Treatment of Standard Surgical Risk Patients Presented at The Society for Vascular Surgery 2021 Vascular Annual Meeting SUNNYVALE, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, is pleased to highlight positive results from an independent analysis of standard surgical risk patients undergoing carotid endarterectomy (CEA) and transcarotid artery revas

Yahoo | August 18, 2021

Silk Road Medical, inc (SILK) Q2 2021 Earnings Call Transcript

Good day, and thank you for standing by, and welcome to the Silk Road Medical's 2021 Second Quarter Earnings. Joining me are Erica Rogers, Chief Executive Officer and Lucas Buchanan, Chief Financial Officer and Chief Operating Officer.

Yahoo | July 30, 2021

Read More 'SILK' Stories Here

SILK Price Returns

1-mo 6.84%
3-mo 8.67%
6-mo 19.61%
1-year -13.34%
3-year N/A
5-year N/A
YTD -9.26%
2020 55.97%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 10.4324 seconds.